Results 141 to 150 of about 84,866 (261)

Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia. [PDF]

Psychol Med
Lu C, Dong Y, Zhai Z, Gao T, Luo M, Chang D, Chen J, Xue J, Zhao Y, Xiang Q, Li X, Ma X, Wei Z, Feng T, Liu D.   +14 more
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Brexpiprazole mitigates hyperprolactinaemia induced by paliperidone in a patient with a history of skin reaction to aripiprazole: case report introducing a new therapeutic approach. [PDF]

BJPsych Open
Humbert-Claude M, Barbé T, Ionescu MC, Khasian M, Khachouf OT, Blanc AL, Lemoullec-Tourtier D, Widmer N.   +7 more
europepmc   +1 more source

Self‐harm in individuals with substance use disorders: Predictive factors and risk model

Addiction, EarlyView.
Abstract Background and aims Substance use disorders are associated with an elevated risk of self‐harm. Currently, clinical and structured assessment of self‐harm risk typically relies on evidence from the general population samples. The aim of this study was to develop a risk model for self‐harm that incorporates predictors specific to individuals ...
Rongqin Yu, Derek K. Tracy, Julia Sinclair, Isabell Brikell, Paul Lichtenstein, Henrik Larsson, Seena Fazel   +6 more
wiley   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

Promoting smoking cessation and preventing relapse to tobacco use following a smokefree mental health in‐patient stay: A multi‐centre randomised controlled feasibility study

Addiction, EarlyView.
Abstract Aims This study assessed the feasibility and acceptability of a new theory‐ and evidence‐based intervention designed to prevent return to pre‐admission smoking behaviours after discharge from a smokefree mental health in‐patient setting in the United Kingdom (UK).
Petal Petersen Williams, Lisa Huddlestone, Emily Shoesmith, Jennifer Sweetman, Heidi Stevens, Alex Mitchell, Fraser Wiggins, Lesley Sinclair, Victoria Exley, Catherine Hewitt, Judith Watson, Qi Wu, Jodi Pervin, Moira Leahy, Claire Paul, Lion Shahab, Michelle Horspool, Tim Coleman, Simon Hough, Elena Ratschen, the SCEPTRE Collaboration team, Lesley Colley, Samantha Brady, John Britton, Simon Gilbody, Steve Parrott, Peter Coventry, Gregor Russell, Paul Galdas   +28 more
wiley   +1 more source

Sleep Disorders in Klinefelter Syndrome and Other Sex Chromosome Aneuploidies: A Narrative Review

Andrology, EarlyView.
ABSTRACT Background Sex chromosome aneuploidies (SCAs) are among the most frequent types of chromosomal aneuploidies and include Klinefelter syndrome (47,XXY and higher‐grade variants), 47,XYY syndrome, Turner syndrome (45,X), and trisomy X (47,XXX).
Roberto Paparella, Fabiola Panvino, Ida Pucarelli, Luigi Tarani   +3 more
wiley   +1 more source

Should Terminal Sedation Be Expanded to Individuals Who Choose to Die Via the Voluntary Stopping of Eating and Drinking?

Bioethics, EarlyView.
ABSTRACT The voluntary stopping of eating and drinking (VSED) is a phenomenon whereby an individual with decision‐making capacity chooses to cease eating and drinking with the intention of ending their own life. This is widely acknowledged as a lawful, albeit uncommon, end‐of‐life decision.
Laura Gilbertson, Dominic Wilkinson, Julian Savulescu   +2 more
wiley   +1 more source

A scoping review of service user experiences of potential harm in early intervention in psychosis services in the UK

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives Early intervention in psychosis (EIP) services provide care for individuals experiencing first‐episode psychosis and are considered both clinically and cost‐effective. While many have positive experiences of EIP, there have also been reports of perceived harm.
Georgie Hudson, India Francis‐Crossley, Craig S. Mackie, Rachel Hiller, James B. Kirkbride, Claire Powell   +5 more
wiley   +1 more source

Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm

British Journal of Pharmacology, EarlyView.
Abstract Antipsychotic drugs targeting dopamine receptors have been used to treat schizophrenia for decades, primarily alleviating positive symptoms such as hallucinations and delusions. However, they provide limited benefit for cognitive and negative symptoms—major contributors to poor outcomes—and are frequently associated with significant side ...
Brian J. Morris, Judith A. Pratt
wiley   +1 more source